

Grifols ranked number one biotech company in Dow Jones Sustainability Indices

- *Included in Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability Europe Index (DJSI Europe) for fourth and fifth consecutive years respectively*
- *Reflects Grifols standing as sustainability leader in light of its commitment to human rights, supply chain management, climate change management as well as health and safety*

Barcelona, Spain - December 16, 2024 – Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it is the number one biotechnology company in the S&P Dow Jones Sustainability Indices (DJSI), ascending to the top position in its fifth straight year of inclusion in the prestigious indices.

This recognition strengthens Grifols' stature as a global leader in sustainability practices and comes as the company achieved its highest-ever S&P Global Corporate Sustainability Assessment (CSA) score. Grifols earned a rating of 70 points, marking a seven-point increase over last year's results and highlighting the company's significant progress and unwavering commitment to sustainability.

In its climb to the top, Grifols has continuously raised its excellence in environmental, social and governance (ESG) practices. As the company advances its sustainability goals, it remains focused on driving long-term value and making a lasting impact toward a more sustainable, ethical and resilient future for all stakeholders.

The Dow Jones Sustainability Index comprises global sustainability leaders identified by S&P Global via the Corporate Sustainability Assessment, an annual evaluation that compares companies across 62 industries. This year, over 13,000 companies were invited to participate, with the index representing the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index.

"It is an honor for Grifols to once again be recognized in the Dow Jones Sustainability Index as one of the world's most sustainable companies," said Nacho Abia, Grifols CEO. "As we continue to deliver consistently strong financial and operational performance, we are very much focused on our commitment to achieving best-in-class ESG practices and our 2030 goals."

Acknowledgments from S&P Global

GRIFOLS

S&P Global has commended Grifols for its progress across ESG categories, including climate strategy, governance and risk management. While Grifols continues to accelerate its transition to a low-carbon economy, DJSI acknowledges Grifols' efforts to foster a more responsible and sustainable supply chain, and awards it the highest scores for its sustainability reporting and business ethics.

On social strategy, S&P Global recognized Grifols' dedication to maintaining a safe and healthy workplace for all employees and its commitment to upholding human rights across all operations. In addition, S&P has once again awarded the company the highest possible score for its commitment to ethical marketing.

For more information on Grifols' ESG initiatives and progress, please visit [Sustainability | Grifols](#) and read more about the company's commitment in the [Biopharmaceutical Industry Sustainability Report | Grifols](#)

INVESTORS:

INVESTORS RELATIONS & SUSTAINABILITY

inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com / Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (M. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (M. +34 650 402 225)

borja_gomez@duomocomunicacion.com

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety

GRIFOLS

from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2023, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

